Stocks · US
BBIO
XNAS
BridgeBio Pharma, Inc. Common Stock
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E—
P/B—
P/S18.13x
EPS$-3.54
ROE27.51%
ROA-56.84%
Dividend yield0.00%
Debt/Equity-0.98
Free cash flow$-435M
Returns and 52-week range
1W+1.50%
1M-10.53%
3M-14.52%
6M-6.91%
1Y+26.67%
YTD-14.41%
52W high$93.42
52W low$52.75
From 52W high-28.32%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| Icon Plc | $13.0B | 38.45 | 6.71 | -1.92% |
| 10X 지노믹스 | $12.7B | — | 15.43 | +28.75% |
| Corcept Therapeutics Inc. | $13.2B | 242.09 | 18.69 | +7.12% |
| Baxter International Inc. | $12.5B | — | 2.02 | -5.69% |
| 트위스트 바이오사이언스 | $13.6B | — | 30.49 | +33.88% |
| 페넘브라 | $12.5B | 77.78 | 8.16 | -1.59% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.